US Patent

US7638536 — 2-Acylaminothiazole derivative or salt thereof

Composition of Matter · Assigned to Astellas Pharma Inc · Expires 2027-07-28 · 1y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof, useful in treating thrombocytopenia.

USPTO Abstract

A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

Drugs covered by this patent

Patent Metadata

Patent number
US7638536
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-07-28
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.